Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC4703 Food Effect and Relative Bioavailability in Healthy Adults
NCT07334080Phase 1Recruiting
- Sponsor
- Eccogene
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ECC4703 in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Eccogene. Primary endpoints: Area Under the Curve from Time Zero to the Last Quantifiable Concentration, Area Under the Curve from Time Zero to Infinity and 8 more. Started Jan 2026; status: recruiting.
02
Drugs
ECC4703
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07334080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334080.